Portola Pharmaceuticals (PTLA) : On Monday, The money flowed into the Portola Pharmaceuticals (PTLA) stock with an uptick to downtick ratio was recorded at 1.41. Transactions worth $5.76 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $4.08 million. The total money flow into the stock was $1.68 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $1.17 million of block transactions on upticks. The total money flow in block trades was $1.17 million. In terms of price action, Portola Pharmaceuticals (PTLA) traded down $0.01 during the session at $27.6. Compared to the previous days closing, the stock was down only by -0.04%. For the week, the stock is 0%, over previous weeks closing.
Shares of Portola Pharmaceuticals, Inc. rose by 3.51% in the last five trading days and 23.01% for the last 4 weeks. Portola Pharmaceuticals, Inc. is up 10.06% in the last 3-month period. Year-to-Date the stock performance stands at -46.18%.
Portola Pharmaceuticals (NASDAQ:PTLA): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $28.25 and $27.26 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $28.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $27.69, notching a gain of 0.29% for the day. The total traded volume was 1,254,899 . The stock had closed at $27.61 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Lis William, director officer (Chief Executive Officer) of Portola Pharmaceuticals Inc, had unloaded 5,675 shares at an average price of $23.86 in a transaction dated on May 2, 2016. The total value of the transaction was worth $135,406.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.